Bone Biologics Corp Warrants
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology use… Read more
Market Cap & Net Worth: Bone Biologics Corp Warrants (BBLGW)
Bone Biologics Corp Warrants (NASDAQ:BBLGW) has a market capitalization of $144.01K ($144.01K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29482 globally and #9768 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bone Biologics Corp Warrants's stock price $15.00 by its total outstanding shares 9601 (9.60K).
Bone Biologics Corp Warrants Market Cap History: 2021 to 2025
Bone Biologics Corp Warrants's market capitalization history from 2021 to 2025. Data shows growth from $6.72K to $144.01K (99.01% CAGR).
Bone Biologics Corp Warrants Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bone Biologics Corp Warrants's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BBLGW by Market Capitalization
Companies near Bone Biologics Corp Warrants in the global market cap rankings as of March 19, 2026.
Key companies related to Bone Biologics Corp Warrants by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Bone Biologics Corp Warrants Historical Marketcap From 2021 to 2025
Between 2021 and today, Bone Biologics Corp Warrants's market cap moved from $6.72K to $ 144.01K, with a yearly change of 99.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $144.01K | -62.50% |
| 2024 | $384.04K | +920.41% |
| 2023 | $37.64K | +21677.78% |
| 2022 | $172.82 | -97.43% |
| 2021 | $6.72K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bone Biologics Corp Warrants was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $144.01K USD |
| MoneyControl | $144.01K USD |
| MarketWatch | $144.01K USD |
| marketcap.company | $144.01K USD |
| Reuters | $144.01K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.